Reports
Reports
Sale
The global immunotherapy drugs market attained a value of USD 222.08 billion in 2023. The market is further expected to grow in the forecast period of 2024-2032 at a CAGR of 11.20% to reach USD 577.42 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
According to the WHO, cancer is the second leading cause of death globally, which led to nearly 10 million deaths in 2020. As a result, the governments and international organisations are increasingly conceptualising initiatives to generate funds while also spreading awareness about various types of cancer and the potential prevention strategies.
These factors are expected to drive the market growth in the coming years. Additionally, the increased expenditure in the healthcare sector and the accessibility to efficient therapeutic techniques, including target-specific and tailored treatments, are also projected to propel the global immunotherapy drugs industry further. Immunotherapy boosts the body’s natural defences to combat the disease by aiding the immune system to recognise and attack cancerous cells.
Geographically, North America is anticipated to account for a significant market share of the immunotherapy drugs industry. This can be attributed to the rising geriatric population in the region and the availability of improved medical facilities.
Immunotherapy is a type of biological therapy, which is used as a treatment for cancer and helps patients fight cancer by providing a boost to the immune system's natural defences to locate and attack cancer cells in the body. Some of the drugs used in immunotherapy are Ipilimumab (Yervoy®), Pembrolizumab (Keytruda®), Nivolumab (Opdivo®), and Atezolizumab (Tecentriq®), among others.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The major types of immunotherapy drugs are:
The market can be broadly categorised, on the basis of therapy area, into:
The EMR report looks into the regional markets of immunotherapy drugs like North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The immunotherapy drugs industry is anticipated to witness growth in both developed as well as developing nations. This can be associated with the rising geriatric population and increasing incidences of chronic illnesses worldwide. Additionally, the increasing expenditure by the leading pharmaceutical companies in the research and development of efficient immunotherapy medications is estimated to propel the industry growth. Furthermore, the growing investments by the governments in the development of healthcare infrastructure are further projected to positively stimulate the market growth in the coming years. Moreover, the market is further expected to be fuelled by the rapid technological advancements in the pharmaceutical industry.
The report presents a detailed analysis of the following key players in the global immunotherapy drugs market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
The comprehensive report looks into the macro and micro aspects of the industry. The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Drug Class |
|
Breakup by Applications |
|
Breakup by Route of Administration |
|
Breakup by End User |
|
Breakup by Distribution Channel |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Immunotherapy Drugs Market Overview
3.1 Global Immunotherapy Drugs Market Historical Value (2017-2023)
3.2 Global Immunotherapy Drugs Market Forecast Value (2024-2032)
4 Global Immunotherapy Drugs Market Landscape
4.1 Global Immunotherapy Drugs Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Immunotherapy Drugs Product Landscape
4.2.1 Analysis by Drug Class
4.2.2 Analysis by Applications
4.2.3 Analysis by Route of Administration
4.2.4 Analysis by End Users
5 Global Immunotherapy Drugs Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Immunotherapy Drugs Market Segmentation
6.1 Global Immunotherapy Drugs Market by Drug Class
6.1.1 Market Overview
6.1.2 Monoclonal Antibodies
6.1.3 Adult Vaccines
6.1.4 Checkpoint Inhibitors
6.1.5 Interferons Alpha and Beta
6.1.6 Interleukins
6.1.7 Other Drugs
6.2 Global Immunotherapy Drugs Market by Applications
6.2.1 Market Overview
6.2.2 Cancer
6.2.3 Autoimmune and Inflammatory Diseases
6.2.4 Infectious Diseases
6.2.5 Others
6.3 Global Immunotherapy Drugs Market by Route of Administration
6.3.1 Market Overview
6.3.2 Oral
6.3.3 Parenteral
6.3.4 Others
6.4 Global Immunotherapy Drugs Market by End User
6.4.1 Market Overview
6.4.2 Hospitals
6.4.3 Specialty Centres
6.4.4 Clinics
6.4.5 Others
6.5 Global Immunotherapy Drugs Market by Distribution Channel
6.5.1 Market Overview
6.5.2 Hospital Pharmacy
6.5.3 Retail Pharmacy
6.5.4 Online Pharmacy
6.5.5 Others
6.6 Global Immunotherapy Drugs Market by Region
6.6.1 Market Overview
6.6.2 North America
6.6.3 Europe
6.6.4 Asia Pacific
6.6.5 Latin America
6.6.6 Middle East and Africa
7 North America Immunotherapy Drugs Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Immunotherapy Drugs Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Immunotherapy Drugs Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Immunotherapy Drugs Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Immunotherapy Drugs Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 Abbott
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 PerkinElmer Inc.
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Illumina, Inc.
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 QIAGEN
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 F. Hoffmann-La Roche Ltd.
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Novartis AG
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 AstraZeneca
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Pfizer Inc.
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Sanofi
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Johnson & Johnson Services, Inc.
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 AbbVie Inc.
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Allergan
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 Merck & Co., Inc.
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
17.14 Amgen Inc.
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisitions
17.14.5 Certifications
17.15 Thermo Fisher Scientific
17.15.1 Financial Analysis
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisitions
17.15.5 Certifications
17.16 Teva Pharmaceutical Industries Ltd.
17.16.1 Financial Analysis
17.16.2 Product Portfolio
17.16.3 Demographic Reach and Achievements
17.16.4 Mergers and Acquisitions
17.16.5 Certifications
17.17 Takeda Pharmaceutical Company Limited.
17.17.1 Financial Analysis
17.17.2 Product Portfolio
17.17.3 Demographic Reach and Achievements
17.17.4 Mergers and Acquisitions
17.17.5 Certifications
17.18 GlaxoSmithKline plc.
17.18.1 Financial Analysis
17.18.2 Product Portfolio
17.18.3 Demographic Reach and Achievements
17.18.4 Mergers and Acquisitions
17.18.5 Certifications
17.19 Lupin Pharmaceuticals, Inc.
17.19.1 Financial Analysis
17.19.2 Product Portfolio
17.19.3 Demographic Reach and Achievements
17.19.4 Mergers and Acquisitions
17.19.5 Certifications
17.20 Lilly
17.20.1 Financial Analysis
17.20.2 Product Portfolio
17.20.3 Demographic Reach and Achievements
17.20.4 Mergers and Acquisitions
17.20.5 Certifications
17.21 Bristol-Myers Squibb Company
17.21.1 Financial Analysis
17.21.2 Product Portfolio
17.21.3 Demographic Reach and Achievements
17.21.4 Mergers and Acquisitions
17.21.5 Certifications
17.22 Boehringer Ingelheim International GmbH
17.22.1 Financial Analysis
17.22.2 Product Portfolio
17.22.3 Demographic Reach and Achievements
17.22.4 Mergers and Acquisitions
17.22.5 Certifications
18 Global Immunotherapy Drugs Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
In 2023, the global immunotherapy drugs market attained a value of nearly USD 222.08 billion.
The market is projected to grow at a CAGR of 11.20% between 2024 and 2032.
The market is estimated to witness a healthy growth in the forecast period of 2024-2032 to reach USD 577.42 billion by 2032.
The major drivers of the industry, such as the rising expenditure in the healthcare industry, rising consciousness pertaining to the availability of cancer treatments, increasing research and development activities, and rapidly growing geriatric global population, are expected to aid the market growth.
The key market trends guiding the growth of the industry include the increased prevalence of cancer cases worldwide.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The significant types of immunotherapy drugs in the industry are monoclonal antibodies, vaccines, interferons alpha and beta, and interleukins, among others.
The significant market divisions, based on therapy areas, include cancer, autoimmune and inflammatory diseases, and infectious diseases, among others.
The major players in the industry are AbbVie Inc., Amgen Inc., AstraZeneca PLC, GlaxoSmithKline PLC, and F. Hoffmann-La Roche AG, among others.
The global immunotherapy drugs market attained a value of nearly USD 222.08 billion in 2023, driven by the rising prevalence of cancer and other chronic illnesses worldwide. Aided by the growing investments in the pharmaceutical industry, the market is expected to witness a further growth in the forecast period of 2024-2032, growing at a CAGR of 11.20%. The market is projected to reach USD 577.42 billion by 2032.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on type, the immunotherapy drugs industry can be segmented into monoclonal antibodies, vaccines, interferons alpha and beta, and interleukins, among others. On the basis of therapy area, the industry can be classified into cancer, autoimmune and inflammatory diseases, and infectious diseases, among others. The major regional markets for immunotherapy drugs are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include AbbVie Inc., Amgen Inc., AstraZeneca PLC, GlaxoSmithKline PLC, and F. Hoffmann-La Roche AG, among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.